Genome editor Intellia Therapeutics poised for new highs after pulling back from high-volume charge at this mark Wednesday. Strong sales, less than desirable earnings and cash flow, but perhaps the momentum is gaining there.
Chart is looking pretty good. Give it a few more days for it to successfully break out.
Contextual immersion trading strategy idea. Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The share price rose after the company announced an expansion of its...
intellia ther daily chart review. best level to buy for 40-50% gains update by projectsyndicate mirror and gap fill level at 12.00 target is S/D zones 17 and 18.50 40/50% gain. put this on your watchlist solid setup. update brought to you by Projectsyndicate. B barnes group inc D1 short into resistance 25% box inc daily update by projectsyndicate ...
Break over long trendline. Break above rectangle bottoming base, backtested the breakout and the 50ma yesterday. Human trials are underway This could really run to the upside and stops are relatively close. First target: 18.50 I might consider entry if the 15-minute RSI weakens again.
1- A huge volume not too long a go with a green candle. 2- Playing on and off the resistance and support line which 16.60ish. 3- A formation of a cup and a handle 4- last couple earnings were good. but my main focus is technical
This looks like a cup & handle pattern. Editas earnings tomorrow could potentially impact this with a sector catalyst. Thoughts?
There is a lot of support at the level we are at now, and conditions looks very oversold. Earnings tomorrow. I remember what happened last earnings, and presenting earnings in the conditions we are at now could potentially be very beneficial for this stock.
NTLA wave analysis and MACD paint a bearish picture, could test down to single digits price...thoughts? NASDAQ:NTLA
PT1 - 13.59, PT2 - 12.97. Pattern not confirmed valid until price closes below neckline. volume profile and MACD direction would indicate that a spike is coming to retest 16 prior to resuming downward trend. short float @ 23.8%
I keep an eye on these 3 "CRISPR" stocks: EDIT CRSP NTLA Now all 3 of these have sold off from highs last summer, to 52-week lows in December. The concern is the amount of debt, and no real revenue for the foreseeable future. Another concern probably has to do with that Chinese scientist who CRISPR'd a human baby. That's concerning to say the least... due to...
NTLA looks ready for price discovery with targets of 55$ and 125$ Strong base has formed at the 24$ level and it has shaken out people who wanted to see a head and shoulders top. This looks more like accumulation than distribution to me. The quarterly has 7 higher lows and is a cup and handle. Bought the base at 25$ and looking to add on confirmation around 32-33$
For anyone who has been holding this for months congrats you have made some great profits in this stock. As you can see there is a Head and Shoulders pattern forming, and for all those TA's out there you know it spells a potential reversal. Biotechs as a whole have enjoyed a nice boost in price mainly due to significant breakthroughs in science as well as all...
The price was hammered down instantly five times now after it tried to overcome the old high (green line). Still it constantly made higher lows and the dips below EMA20 got shallower. When the green line is taken for good, a lot of built up pressure may lead to a rapid bull-run.